Navigation Links
diaDexus, Inc. Pre-Announces 2011 Q4, YE Revenue and 2012 Guidance
Date:1/9/2012

chief financial officer and to attract, retain and motivate other qualified personnel: its relationship with key customers; diaDexus' reliance on sole source third party manufacturers to manufacture and supply diaDexus' main reagent and the PLAC Test; the effects of government regulations and the company's ability to comply with such regulations; diaDexus' ability to demonstrate that treatment of individuals based on their Lp-PLA2 levels improves clinical outcomes in prospective clinical studies; the rate of adoption of the PLAC Test by doctors and laboratories; third party payors' acceptance of and reimbursement for the PLAC Test; downward pressure on diaDexus' product pricing, particularly from the company's largest customers; the adequacy of the company's intellectual property rights; diaDexus' limited revenue and cash resources; diaDexus' ability to accurately forecast revenues prior to review and issuance of its financial statements for the year ending December 31, 2011; and diaDexus' significant corporate expenses, including real estate liabilities and expenses associated with being a public company. Additional factors that could cause diaDexus' results to differ materially from those described in the forward-looking statements can be found in diaDexus' most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and other reports filed with the Securities and Exchange Commission, and available at the SEC's web site at www.sec.gov. The information set forth herein speaks only as of the date hereof, and diaDexus disclaims any intention and does not assume any obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. diaDexus, Inc. to Present at the Canaccord Genuity Healthcare Conference
2. diaDexus, Inc. Reports 45% Year-Over-Year Revenue Growth for 2011 Second Quarter
3. diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players
4. RSB Spine, LLC Announces 2011 Revenue Growth
5. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
6. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
7. Neogen Reports First Quarter Revenue and Net Income Increases
8. Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010
9. Cord Blood America Six Month Revenues Up 61 Percent; Gross Profit Up 100 Percent
10. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
11. NxStage® Reports Record Revenue for the First Quarter of Fiscal 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015 ... announced the addition of the "Oxidative ... Services), Test Type (Indirect, Enzyme-based, Reactive Oxygen ... End Users - Global Forecast to 2020" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , The ...
(Date:6/1/2015)... June 1, 2015 GenomeDx Biosciences ... analysis platform, successfully classified various subtypes of ... of certain biomarkers, including one type associated ... unique genomic signature has potential as a ... chemotherapy in patients with muscle-invasive bladder cancers ...
(Date:6/1/2015)... June 1, 2015  Novartis is highlighting data ... CTL019, an investigational chimeric antigen receptor (CAR) T ... treatment of specific types of hard-to-treat non-Hodgkin lymphoma. ... University of Pennsylvania,s Perelman School of Medicine (Penn) ... large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Regis ... and manufacturing of chiral stationary phases (CSPs) for ... for its current and presenting solutions for new ... its portfolio. This valuable addition to its core ... effective advantage that can tackle projects for the ...
Breaking Biology Technology:Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3
... Blood ... Expertise, PALO ALTO, Calif., May 29 Pelikan Technologies ... announced the appointment of Dennert (Denny) Ware to its,board of ... of Kinetic Concepts, Inc. (KCI), a global medical,technology company, Mr. ...
... China, May 29 /Xinhua-PRNewswire-FirstCall/ -- China,Biologic Products, Inc. ... of the leading plasma-based pharmaceutical companies in the,People,s ... announced that the,Company has been approved by the ... commence the production of Human Albumin 12.5g/vial (25%,50 ...
... Clarient, Inc.,(Nasdaq: CLRT ), a premier ... oncologists and the pharmaceutical industry,today announced that, effective ... will join Clarient as Senior Vice President and ... years experience as a public,company CFO in life ...
Cached Biology Technology:Pelikan Technologies Appoints Denny Ware to Board of Directors 2Pelikan Technologies Appoints Denny Ware to Board of Directors 3China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml) 2China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml) 3Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 2Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 3Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 4Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 5
(Date:4/27/2015)... OXFORD, Conn. , Apr. 27, 2015 ... "Company"), a biometric authentication company focused on the growing ... will commence shipping to pre-order customers the first week ... pre-orders through the month of May. ... is a significant milestone for the company as Wocket® ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... 21 June, 2010 The Editors of the leading ... announce that the third Ahmed Zewail Prize in Molecular Sciences ... University of California, Berkeley, USA, for his outstanding contributions to ... monetary award of $20,000 and will be presented during the ...
... technology university, Nanyang Technological University (NTU), and Israel,s ... today announced a new collaboration to jointly offer ... The NTU-Technion Joint PhD degree programme is a ... Materials Science and Bioengineering. Significantly, the joint PhD ...
... Elsevier announced the launch of PeerChoice, a new pilot ... reviewers now have the freedom to choose which articles they ... and interest, efficiency and effectiveness of the peer review process ... three months, starting in June. PeerChoice reverses ...
Cached Biology News:Elsevier announces the winner of the Ahmed Zewail prize in molecular sciences 2NTU ramps up collaboration with Israel's top university 2NTU ramps up collaboration with Israel's top university 3Elsevier pilots PeerChoice in Chemical Physics Letters 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
... cyclin required for G1-phase progression and is ... cyclin D2 can phosphorylate pRB when associated ... Human, Mouse, and Rat. Others-not tested. ... suited for neutralization of cyclin D2 activity ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: